Alnylam and Collaborators Publish Clinical Trial Results with RNAi ... Wall Street Journal FAP patients have a life expectancy of five to 15 years from symptom onset, and the only treatment options for early stage disease are liver transplantation and tafamidis (approved in Europe). The mean survival for FAC patients is approximately 2.5 ... |
